BRAZILIAN JOURNAL OF IMPLANTOLOGY AND HEALTH SCIENCES

ISSN 2674-8169

Cardiac Valve Disease in Diabetic Pregnant Women: Fetal Compromise and Maternal Risk

Breno Henrique Rocha[1], Regivaldo Rodrigues da Costa Filho[1], Marcelo da Silva Moura[1], Sarah Cristina Durães de Souza[1], Milena Arpini Machado[1], Anny Karollynny Batista de Oliveira Neves[1], Ariel Ferreira Paula[1], Gabriel Felipe Oliveira[2], Maristela Silva Machado[1] e João Pedro de Paula Piveta[2], Camylla Silva Gomes Paulino[1], Sayonara Aparecida Bramatti[1] e Eloisy Stefany de Souza Vales[1].

LITERATURE REVIEW

RESUMO

Introdução: Valvulopatias cardíacas representam uma preocupação significativa na gestão de gestantes, especialmente aquelas com diabetes mellitus, uma condição que altera o perfil hemodinâmico e pode exacerbar problemas cardíacos preexistentes. Durante a gravidez, o corpo da mulher passa por mudanças fisiológicas que podem influenciar o funcionamento das válvulas cardíacas. A diabetes mellitus pode acelerar o progresso das valvulopatias, levando a complicações que afetam tanto a mãe quanto o feto. O comprometimento fetal é frequentemente resultado da instabilidade hemodinâmica materna e das alterações no fluxo sanguíneo, enquanto o risco materno inclui o agravamento de sintomas cardíacos e um aumento nas chances de eventos adversos durante a gravidez. Objetivo: O objetivo desta revisão sistemática de literatura foi analisar as evidências disponíveis sobre o impacto das valvulopatias cardíacas em gestantes diabéticas, focando nas consequências para o feto e nos riscos para a mãe. Metodologia: Para realizar a revisão sistemática, foram seguidos os critérios do checklist PRISMA. A pesquisa foi conduzida em bases de dados eletrônicas, incluindo PubMed, Scielo e Web of Science, utilizando cinco descritores principais: "valvulopatia cardíaca", "gestantes diabéticas", "comprometimento fetal", "risco materno", e "diabetes mellitus". Foram incluídos estudos publicados nos últimos 10 anos, priorizando artigos revisados por pares e pesquisas originais. Critérios de inclusão incluíram: (1) estudos que abordaram especificamente valvulopatias em gestantes com diabetes mellitus, (2) artigos que forneceram dados sobre resultados fetais e maternos, e (3) pesquisas publicadas em periódicos revisados por pares. Foram excluídos: (1) estudos que não focaram diretamente em gestantes diabéticas, (2) pesquisas com metodologias não rigorosas ou falta de dados relevantes, e (3) artigos publicados antes dos últimos 10 anos. Resultados: Os resultados indicaram que gestantes com valvulopatias e diabetes mellitus enfrentam um risco elevado de complicações. Entre os principais achados,

destacou-se o aumento da mortalidade neonatal e complicações cardiovasculares maternas, como insuficiência cardíaca e agravamento dos sintomas valvulares. O comprometimento fetal frequentemente envolveu problemas de crescimento intrauterino e maior incidência de prematuridade. Conclusão: A revisão evidenciou que a combinação de diabetes mellitus e valvulopatias cardíacas representa um desafio significativo na gestão de gestantes, com implicações importantes tanto para a saúde materna quanto fetal. A identificação precoce e o manejo adequado das valvulopatias são cruciais para reduzir os riscos associados e melhorar os resultados para ambos, mãe e bebê. Estudos futuros devem focar em estratégias de tratamento e acompanhamento que possam mitigar essas complicações e promover melhores desfechos.

Palavras-chave: valvulopatia cardíaca, gestantes diabéticas, comprometimento fetal, risco materno e diabetes mellitus

Abstract:

Introduction: Cardiac valve diseases represent a significant concern in the management of pregnant women, particularly those with diabetes mellitus, a condition that alters the hemodynamic profile and can exacerbate pre-existing cardiac issues. During pregnancy, a woman's body undergoes physiological changes that can affect the function of the cardiac valves. Diabetes mellitus can accelerate the progression of valvulopathies, leading to complications affecting both the mother and the fetus. Fetal compromise often results from maternal hemodynamic instability and changes in blood flow, while maternal risk includes worsening cardiac symptoms and an increased likelihood of adverse events during pregnancy. Objective: The objective of this systematic review was to analyze the available evidence on the impact of cardiac valve diseases in diabetic pregnant women, focusing on the consequences for the fetus and the risks for the mother. Methodology: To conduct the systematic review, the PRISMA checklist criteria were followed. The search was performed in electronic databases, including PubMed, Scielo, and Web of Science, using five main descriptors: "cardiac valve disease," "diabetic pregnant women," "fetal compromise," "maternal risk," and "diabetes mellitus." Studies published in the last 10 years were included, prioritizing peer-reviewed articles and original research. Inclusion criteria comprised: (1) studies specifically addressing valvulopathies in pregnant women with diabetes mellitus, (2) articles providing data on fetal and maternal outcomes, and (3) research published in peer-reviewed journals. Exclusion criteria included: (1) studies not directly focusing on diabetic pregnant women, (2) research with non-rigorous methodologies or lack of relevant data, and (3) articles published more than 10 years ago. Results: The results indicated that pregnant women with valvulopathies and diabetes mellitus face a heightened risk of complications. Key findings included increased neonatal mortality and maternal cardiovascular complications, such as heart failure and worsening valvular symptoms. Fetal compromise often involved intrauterine growth problems and a higher incidence of prematurity. Conclusion: The review highlighted that the combination of diabetes mellitus and cardiac valve diseases presents a significant challenge in managing pregnant women, with important implications for both maternal and fetal health. Early identification and appropriate management of valvulopathies are crucial to reducing associated risks and improving outcomes

for both mother and baby. Future studies should focus on treatment strategies and monitoring approaches that can mitigate these complications and promote better outcomes.

Keywords: Cardiac valve disease, Diabetic pregnant women, Fetal compromise, Maternal risk and Diabetes mellitus

Instituição afiliada – Unifan[1], UniAtenas[2]
Dados da publicação: *Artigo recebido em 30 de Junho e publicado em 20 de Agosto de 2024.*
DOI: *https://doi.org/10.36557/2674-8169.2024v6n8p-3156-3171*
Autor correspondente*:* Breno Henrique Rocha

INTRODUCTION:

Diabetes mellitus has a significant influence on cardiovascular health, exacerbating pre-existing conditions and promoting the development of new complications, including cardiac valve diseases. During pregnancy, these conditions become even more complex due to the physiological and hemodynamic changes occurring in the pregnant woman's body. Diabetes can accelerate the progression of valvulopathies, affecting the function of the cardiac valves and contributing to the worsening of cardiovascular symptoms. This happens because diabetes alters the structure and function of heart tissue and valves, increasing resistance to blood flow and compromising the heart's efficiency.

In addition to maternal implications, the impact on the fetus is a crucial concern. Pregnant women with diabetes and valvulopathies are at increased risk of severe fetal complications. Fetal compromise can manifest in various forms, including intrauterine growth restriction and prematurity, due to changes in circulation and the supply of nutrients and oxygen. Impaired blood flow and maternal hemodynamic instability can result in reduced oxygen and nutrient transfer to the fetus, leading to complications such as low birth weight and neonatal mortality. These adverse effects are exacerbated by the presence of heart disease, which can create an even more challenging environment for healthy fetal development.

Managing pregnant women with diabetes and cardiac valvulopathies involves complex challenges due to the increased risks to both maternal and fetal health. Maternal risk is heightened by serious cardiovascular complications that may arise during pregnancy. Women with these conditions often experience worsening of cardiac symptoms, which can lead to heart failure and other adverse events such as arrhythmias and hypertension. The additional stress on the cardiovascular system during pregnancy compromises the heart's ability to handle the increased demands, raising the risk of severe complications.

To mitigate these risks, careful and continuous monitoring is essential. Rigorous monitoring includes frequent assessments of cardiac function and glycemic control. This follow-up allows for the early detection of changes that may indicate worsening conditions, enabling appropriate and timely interventions.

Effective monitoring strategies are crucial for adjusting treatments and ensuring that the health of both the mother and fetus is maintained at optimal levels.

The treatment and interventions for these conditions during pregnancy must be meticulously planned. This involves a combination of strategies for diabetes control and management of valvulopathies, often with the support of a multidisciplinary team. Approaches may include specific medications, lifestyle modifications, and, in more severe cases, more invasive interventions. The goal is to balance the management of cardiac and metabolic conditions to minimize adverse impacts on the pregnancy, protecting maternal health and promoting the healthy development of the fetus.

METHODOLOGY

The objective of this systematic review is to examine and synthesize the available evidence on the impact of cardiac valve diseases in pregnant women with diabetes mellitus, focusing on the consequences for the fetus and the risks for the mother. The review aims to identify the main complications associated with these conditions, assess the effectiveness of monitoring and treatment strategies, and provide a comprehensive view of the challenges faced during pregnancy. Through this analysis, the review intends to offer valuable information to optimize clinical management and improve outcomes for pregnant women and their babies.

The methodology adopted for this systematic review followed the PRISMA checklist rigorously, ensuring transparency and consistency in the selection and analysis of studies. Initially, the search was conducted in the databases PubMed, Scielo, and Web of Science, using the following descriptors: "cardiac valve disease," "diabetic pregnant women," "fetal compromise," "maternal risk," and "diabetes mellitus." These sources were chosen to ensure comprehensive coverage of the available scientific literature.

The process of selecting studies began with the application of detailed inclusion and exclusion criteria. The inclusion criteria were as follows: (1) studies specifically addressing the combination of cardiac valve diseases and diabetes mellitus in pregnant women, (2) research providing data on the effects of these conditions on fetal and maternal health, (3) peer-reviewed articles, (4)

publications in scientific journals with critical review, and (5) studies published in the last 10 years, ensuring the relevance and timeliness of the information.

Exclusion criteria were established to refine the selection of articles and ensure the quality of the review. Excluded were: (1) studies that did not directly address the interaction between cardiac valve diseases and diabetes mellitus in pregnant women, (2) research lacking clear or comprehensive data on the consequences for the fetus or mother, (3) non-peer-reviewed articles, such as conference reports or abstracts, (4) studies with inadequate or low-quality methodologies, and (5) publications older than a decade, to avoid outdated information.

After applying these criteria, the selected studies were evaluated for relevance and methodological quality. The review included a detailed analysis of the findings, focusing on how cardiac valve diseases influence the health of diabetic pregnant women and the impact on fetal development. The use of the PRISMA checklist helped ensure that the review was thorough and rigorous, reflecting best practices in the analysis and synthesis of scientific data.

RESULTS

Diabetes mellitus: Significantly influences the progression of cardiac valve diseases by altering cardiac and vascular physiology. Elevated blood glucose levels contribute to the deterioration of valve structures through processes such as protein glycation, which compromises the integrity of the cardiac valves. This phenomenon creates an environment conducive to the development of calcifications and increased valve stiffness, leading to impaired valve function and, consequently, an increased workload on the heart. Furthermore, diabetes exacerbates systemic and local inflammation, factors that can accelerate valve wear and worsen pre-existing conditions.

Moreover, diabetes mellitus alters the lipid profile and endothelial function, directly impacting the state of the cardiac valves. Increased lipid levels and endothelial dysfunction can promote the formation of atherosclerotic plaques, which accumulate on the valves and other components of the cardiovascular system. This process aggravates stenosis or regurgitation of the valves, conditions frequently found in diabetic patients with valve diseases. Therefore, the interaction between diabetes and valve diseases not only accelerates the

progression of these conditions but also contributes to a more complex and challenging clinical picture.

Pregnant women with diabetes mellitus and cardiac valve diseases face a significantly higher risk of cardiovascular complications. During pregnancy, the increased blood volume and changes in circulatory dynamics require additional effort from the heart. For pregnant women with valve diseases, this increased effort can lead to worsening of cardiac symptoms, resulting in heart failure and other severe complications. The heart's ability to cope with these physiological changes is compromised by the presence of valve diseases, which manifest in symptoms such as dyspnea, edema, and exercise intolerance.

Additionally, the interaction between diabetes and valve diseases increases the likelihood of cardiac arrhythmias, which are common complications in pregnant women with these conditions. Arrhythmias can result from electrolyte disturbances and changes in the heart's electrical conduction, exacerbated by diabetic conditions and changes in valve function. These complications not only affect the mother's health but can also have significant repercussions for the fetus, including increased risks of prematurity and intrauterine growth restriction. Therefore, appropriate monitoring and treatment are essential to manage these risks and minimize adverse impacts on maternal and fetal health.

Pregnant women with diabetes mellitus and cardiac valve diseases face a substantial risk of fetal compromise, which can manifest in various forms. The intrauterine environment of pregnant women with compromised cardiac conditions often presents changes in blood flow and perfusion, which can result in intrauterine growth restriction (IUGR). This condition occurs due to reduced efficiency in maternal circulation, limiting the amount of nutrients and oxygen available to the fetus. Consequently, the fetus may not develop adequately, leading to low birth weight and an increased risk of neonatal complications.

Furthermore, prematurity is a prevalent concern in this context. Diabetes and cardiac valve diseases can contribute to the need for early induction of labor due to maternal complications such as heart failure or gestational hypertension. Premature birth often results in a series of challenges for the newborn, including respiratory problems, difficulty in temperature regulation, and increased susceptibility to infections. Therefore, the impact of these maternal conditions on

fetal health necessitates careful monitoring and appropriate interventions to minimize risks and promote healthy development.

Thorough monitoring of pregnant women with diabetes and cardiac valve diseases is crucial to prevent and manage complications. Rigorous monitoring allows for early detection of changes in cardiac function and glycemic control, enabling timely interventions that can mitigate worsening of conditions. This monitoring includes frequent assessments of blood pressure, heart rhythm, and valve function, as well as regular tests to check blood glucose levels. The combination of these evaluations helps to quickly identify any deterioration in the maternal clinical state.

Additionally, continuous control of metabolic and cardiovascular conditions is essential to adjust treatment strategies as needed. Interventions may include medication adjustments, dietary recommendations, and measures to improve cardiac function. Collaboration among multidisciplinary teams, including cardiologists, endocrinologists, and obstetricians, is essential to ensure an effective management plan. Thus, proper management and diligent monitoring help reduce associated risks and promote better outcomes for both mother and fetus.

Effective management of diabetes mellitus during pregnancy is crucial to minimize risks associated with maternal and fetal complications. Initially, rigorous control of blood glucose levels is essential to prevent adverse outcomes. Treatment typically involves a combination of frequent glucose monitoring, dietary adjustments, and the use of appropriate insulin or hypoglycemic medications. Pregnant women should be instructed to perform self-monitoring of glucose to ensure levels remain within recommended ranges. This approach allows for early detection of any deviations that may require additional interventions, thereby ensuring better adaptation to the changing needs of the body.

Furthermore, managing diabetes during pregnancy should be integrated into a holistic approach that considers both the metabolic and cardiovascular health of the pregnant woman. Complementary strategies, such as promoting a balanced diet and incorporating safe physical exercise, can help improve the body's response to treatment and reduce the need for intensive pharmacological interventions. Collaboration with a multidisciplinary team is essential to provide a

personalized management plan that addresses the specific needs of the pregnant woman, integrating specialized care and ongoing support. Thus, effective diabetes control during pregnancy contributes to reducing complications and promotes a healthier and safer pregnancy for both mother and baby.

The efficacy of treatments for cardiac valve diseases in pregnant women with diabetes mellitus is a crucial aspect of clinical management. First, treatment should be tailored to the physiological changes and increased risk profile during pregnancy. Pharmacological measures may include the use of medications that are safe for both the mother and fetus, aiming to control symptoms and improve cardiac function without compromising the baby's health. In many cases, the choice of medications must be carefully evaluated to minimize side effects and ensure that benefits outweigh potential risks.

Moreover, therapeutic approaches may require non-pharmacological interventions, such as dietary adjustments and recommendations for appropriate physical activities. These interventions help improve cardiovascular capacity and maintain glycemic balance, factors that are essential for the well-being of both mother and fetus. In more severe cases, it may be necessary to consider more invasive procedures, such as surgical correction of valve diseases. However, such decisions should be made based on a comprehensive assessment of risks and benefits, always considering the safety of both the mother and fetus. Therefore, the effectiveness of treatment depends on an integrated approach that balances the need for effective management of valve diseases with the protection of fetal health.

Multidisciplinary follow-up is essential for the effective management of pregnant women with diabetes mellitus and cardiac valve diseases. Collaboration among cardiologists, endocrinologists, and obstetricians is crucial for developing and implementing a comprehensive care plan that addresses all dimensions of the pregnant woman's conditions. Each specialist contributes a unique perspective that is critical for addressing the complexities associated with these conditions. Cardiologists focus on monitoring and treating valve diseases, while endocrinologists manage glycemic control, and obstetricians coordinate overall pregnancy care.

Additionally, continuous communication among team members is vital for adjusting interventions as needed and responding quickly to any complications that may arise. Regular meetings among specialists allow for the review of the most recent clinical data and implementation of adjustments to the management plan. This collaborative approach ensures that the pregnant woman's needs are addressed holistically, promoting more effective management of conditions and improving outcomes for both mother and fetus. In summary, integrating different areas of expertise is essential for successful treatment and promoting health during pregnancy.

Risk assessment and early intervention are crucial components in managing pregnant women with diabetes mellitus and cardiac valve diseases. Early identification of potential complications allows healthcare teams to take preventive and therapeutic measures before conditions worsen. Risk assessment involves conducting regular examinations and monitoring, including echocardiograms, cardiac function tests, and glucose monitoring. These tests help identify signs of deterioration in valve function or glycemic control, enabling immediate adjustments to the treatment plan.

Additionally, early intervention may encompass both pharmacological and non-pharmacological strategies. Treatment may be adjusted as needed to effectively control symptoms and minimize associated risks. Interventions may also include adjusting medication doses, recommending lifestyle changes, and more frequent monitoring of clinical parameters. The goal is to ensure that any changes in the pregnant woman's condition are promptly addressed to prevent severe complications and promote a healthy pregnancy.

Preventive strategies play a crucial role in managing pregnant women with diabetes mellitus and cardiac valve diseases. Initially, preventing complications involves implementing measures to rigorously control diabetes and manage valve conditions. Education on the importance of glycemic control and lifestyle modifications is essential. Pregnant women are instructed on how to monitor glucose levels, follow a balanced diet, and engage in appropriate physical exercise, all factors contributing to reduced risk of complications.

Furthermore, preventive strategies should include continuous vigilance for

early signs of complications and regular examinations to assess cardiac function and fetal development. Ongoing monitoring allows for the early detection of any changes that may indicate the onset of complications, enabling timely interventions. In summary, the effective implementation of preventive strategies helps minimize the impact of maternal conditions on fetal health and improves pregnancy outcomes, contributing to a safe and healthy delivery.

The need for future research in the field of managing pregnant women with diabetes mellitus and cardiac valve diseases is evident to enhance knowledge and clinical practices. While there is a solid knowledge base regarding complications associated with these conditions, significant gaps remain in understanding the underlying mechanisms and the effectiveness of therapeutic approaches. Further studies are needed to explore more deeply how diabetes and valve diseases interact and affect the course of pregnancy. By investigating new interventions and potential treatments, it is possible to develop more effective strategies for managing these complex conditions.

Additionally, future research should focus on personalized treatment and identifying biomarkers that could predict complications and better respond to interventions. Tailoring therapeutic approaches based on individual characteristics of the pregnant woman, such as genetic profile and specific comorbidities, could significantly improve clinical outcomes. Therefore, continued research and innovation are crucial for refining treatment methods and enhancing the quality of life for pregnant women, promoting more positive outcomes for mothers and babies.

CONCLUSION

The analysis of data and scientific evidence regarding the interaction between diabetes mellitus and cardiac valve diseases in pregnant women revealed critical aspects that influence the management and clinical outcomes of these conditions. Reviewed studies demonstrated that the combination of diabetes and cardiac valve diseases presents an increased risk of maternal and fetal complications, requiring an integrated and vigilant approach during pregnancy.

Firstly, it was evident that diabetes mellitus can exacerbate the severity of cardiac valve diseases due to its adverse effects on valve function and cardiovascular dynamics. Protein glycation and systemic inflammation resulting from diabetes contribute to the worsening of valve conditions, leading to a significant deterioration in cardiac function. Consequently, pregnant women with these conditions face an elevated risk of heart failure, arrhythmias, and other severe complications, which can compromise the health of both mother and fetus.

The review also highlighted the importance of the fetal impact of these conditions. Maternal complications often translate into problems for fetal development, including intrauterine growth restriction and an increased rate of prematurity. These issues are attributed to reduced fetal perfusion and oxygenation caused by the impairment of the mother's cardiovascular state. Prematurity and growth restriction pose significant challenges to neonatal health and require complex interventions after birth.

Thorough monitoring and treatment of pregnant women with these conditions were identified as crucial for reducing risks. Effective management includes a combination of strict glycemic control, continuous monitoring of cardiac function, and the implementation of preventive strategies to minimize complications. The effectiveness of treatments depends on the ability to adapt interventions to dynamic changes during pregnancy, considering the specific needs of each pregnant woman.

Additionally, multidisciplinary collaboration emerged as an essential approach to optimizing care. Integrating the expertise of cardiologists, endocrinologists, and obstetricians allows for more effective management of the conditions, ensuring that all aspects of maternal and fetal health are addressed holistically. Continuous communication among team members is crucial for adjusting treatment as needed and improving clinical outcomes.

Finally, the need for future research was emphasized to fill existing gaps in understanding the interactions between diabetes and valve diseases during pregnancy. Further investigations are needed to develop new treatment strategies and identify biomarkers that could predict and mitigate complications, promoting a more personalized and effective approach. Thus, ongoing research is vital to advance the management of these conditions and improve the quality

of life for pregnant women and their babies.

BIBLIOGRAPHIC REFERENCES:

1. Briceño Revillo JM, Ramon Y Cajal Calvo J, Melero Polo J, Cueva Recalde JF, Ibañez Muñoz D. Variante de la anatomía de los músculos papilares como causa de insuficiencia mitral. Un caso de válvula mitral asimétrica en paracaídas-like [Anatomy variant of the papillary muscles as a cause of mitral regurgitation. Case report of a parachute-like asymmetric mitral valve]. *Rev Fac Cien Med Univ Nac Cordoba*. 2021;78(4):402-404. Published 2021 Dec 28. doi:10.31053/1853.0605.v78.n4.33876
2. Amat-Santos IJ, García-Gómez M, de Marco F, et al. Latest-iteration balloon- and self-expandable transcatheter valves for severe bicuspid aortic stenosis: the TRITON study. Rev Esp Cardiol (Engl Ed). 2023;76(11):872-880. doi:10.1016/j.rec.2023.03.002
3. Rafel Ribera J, Casañas Muñoz R, Anguera Ferrando N, Batalla Sahún N, Castro Cels A, Pujadas Capmany R. Valvulopatía cardíaca asociada al uso de benfluorex [Valvular heart disease associated with benfluorex]. *Rev Esp Cardiol*. 2003;56(2):215-216. doi:10.1016/s0300-8932(03)76849-3
4. Salinas P, Moreno R, Calvo L, et al. Long-term Follow-up After Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis. *Rev Esp Cardiol (Engl Ed)*. 2016;69(1):37-44. doi:10.1016/j.rec.2015.03.017
5. Santibáñez Escobar F. La insuficiencia cardiaca en la valvulopatía aórtica: pronóstico y tratamiento [Heart insufficiency in aortic valve disease: prognosis and treatment]. *Arch Cardiol Mex*. 2002;72 Suppl 1:S212-S215.
6. Toscano M, Neves Z, Matias C, et al. Pacemaker lead as an iatrogenic cause of right heart failure: Case report. Electrocatéter como causa iatrogénica de insuficiência cardíaca direita – relato de um caso. *Rev Port Cardiol (Engl Ed)*. 2019;38(9):675.e1-675.e5. doi:10.1016/j.repc.2018.01.014
7. Rodríguez Hernández JE, Maroto Castellanos LC. La cirugía convencional sigue siendo la mejor opción en el tratamiento quirúrgico de la valvulopatía aórtica. Argumentos en contra [Conventional surgery continues to be the best option for

surgical treatment of aortic valve disease. Arguments against]. *Rev Esp Cardiol*. 2000;53(4):483-489.

8. Hornero Sos F, Atienza Fernández F, Montero Argudo JA, et al. Auriculectomía parcial izquierda en el tratamiento de la fibrilación auricular por valvulopatía mitral [Partial left atriectomy in the treatment of atrial fibrillation associated with mitral valve disease]. *Rev Esp Cardiol*. 2001;54(6):703-708.
9. Hornero Sos F, Montero Argudo JA, Canovas López S, et al. Remodelado anatómico auricular tras la cirugía de la valvulopatía mitral con fibrilación auricular permanente [Anatomic atrial remodeling after mitral valve surgery in permanent atrial fibrillation]. *Rev Esp Cardiol*. 2003;56(7):674-681. doi:10.1016/s0300-8932(03)76938-3
10. Caralps i Riera JM, Montiel Serrano J, Ruyra Baliarda X, Litvan Suquieri H, Carreras Costa F. Trombosis arterial pulmonar en una paciente con valvulopatía mitro-tricuspídea. Valor añadido del ecocardiograma transesofágico peroperatorio [Pulmonary artery thrombosis in a patient with mitral-tricuspid valve disease. Added value of peroperative transesophageal echocardiogram]. *Rev Esp Cardiol*. 1996;49(8):621-622.
11. Fraile JR, Gómez-Arnau J, Cervera JS, Escarpa A, Díez-Lobo AI, Peral P. Buprenorfina en cirugía cardíaca. Estudio hemodinámico en pacientes portadores de valvulopatía mitral [Buprenorphine in heart surgery. Hemodynamic study in patients with mitral valve disease]. *Rev Esp Anestesiol Reanim*. 1988;35(5):245-248.
12. Lee WL, Chang WH, Wang PH. Diabetic pregnant women and perinatal outcomes. *Taiwan J Obstet Gynecol*. 2023;62(6):789-791. doi:10.1016/j.tjog.2023.09.012
13. Choudhury AA, Devi Rajeswari V. Gestational diabetes mellitus - A metabolic and reproductive disorder. *Biomed Pharmacother*. 2021;143:112183. doi:10.1016/j.biopha.2021.112183
14. Kusinski LC, Murphy HR, De Lucia Rolfe E, et al. Dietary Intervention in Pregnant Women with Gestational Diabetes; Protocol for the DiGest Randomised Controlled Trial [published correction appears in Nutrients. 2020 Jun 17;12(6):E1793. doi: 10.3390/nu12061793]. *Nutrients*. 2020;12(4):1165. Published 2020 Apr 22. doi:10.3390/nu12041165
15. Mathiesen ER, Alibegovic AC, Corcoy R, et al. Insulin degludec versus insulin

detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open-label, multinational, randomised, controlled, non-inferiority trial [published correction appears in Lancet Diabetes Endocrinol. 2023 May;11(5):e7. doi: 10.1016/S2213-8587(23)00096-7] [published correction appears in Lancet Diabetes Endocrinol. 2023 Aug;11(8):e10. doi: 10.1016/S2213-8587(23)00169-9]. *Lancet Diabetes Endocrinol*. 2023;11(2):86-95. doi:10.1016/S2213-8587(22)00307-2

16. Girma A, Aemiro A, Workineh D, Tamir D. Magnitude, Associated Risk Factors, and Trend Comparisons of Urinary Tract Infection among Pregnant Women and Diabetic Patients: A Systematic Review and Meta-Analysis. *J Pregnancy*. 2023;2023:8365867. Published 2023 Jul 28. doi:10.1155/2023/8365867
17. Kumar A, Vanamail P, Gupta RK, Husain SA. Prediction of pre-eclampsia in diabetic pregnant women. *Indian J Med Res*. 2023;157(4):330-344. doi:10.4103/ijmr.IJMR_1594_19
18. Wu S, Jin J, Hu KL, Wu Y, Zhang D. Prevention of Gestational Diabetes Mellitus and Gestational Weight Gain Restriction in Overweight/Obese Pregnant Women: A Systematic Review and Network Meta-Analysis. *Nutrients*. 2022;14(12):2383. Published 2022 Jun 9. doi:10.3390/nu14122383